Monday morning brought a double shot of positive phase III data in second-line renal cell carcinoma (RCC) from Exelixis Inc.'s multityrosine kinase inhibitor cabozantinib and Bristol-Myers Squibb Co.'s nivolumab, even as the prospect of combination therapy heralds a changing landscape in RCC treatment.